Lexeo Therapeutics, Inc. (LXEO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on the stock and has a $15.00 price target.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Mitchell Kapoor has given his Buy rating due to a combination of factors that highlight Lexeo Therapeutics, Inc.’s promising position in the gene therapy market. One of the primary reasons is the positive data from Lexeo’s LX2020 therapy, which has shown significant efficacy in reducing premature ventricular contractions (PVCs) in patients with PKP2-associated arrhythmogenic cardiomyopathy (ACM). This is particularly noteworthy when compared to a competitor’s therapy, which demonstrated less consistent results.
Another critical factor influencing Kapoor’s rating is the superior safety profile of Lexeo’s LX2020. Unlike its competitor, which reported serious adverse events including elevated liver enzymes, Lexeo’s therapy has not been associated with any treatment-related serious adverse events. This safety advantage is attributed to Lexeo’s use of a cardiospecific capsid, AAVrh10, which allows for effective dosing at lower levels, reducing potential side effects. These factors combined make Lexeo’s stock an attractive investment opportunity, according to Kapoor.
According to TipRanks, Kapoor is an analyst with an average return of -25.7% and a 24.71% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Halozyme, and Summit Therapeutics.
In another report released on May 12, RBC Capital also maintained a Buy rating on the stock with a $20.00 price target.